US/UK/Canada

Share

Quotes

Liv developed a very promising prototype that is now ready for the first clinical tests, which is an important milestone in the R&D process. The acquisition by Cline will advance the development of the product, and I’m confident that it will create great benefits for patients and health care
Liv Diagnostics CEO and co-founder Johan Bjurquist
After three years of being apart of a project that has resulted in the development of Liv Diagnostics, we are very excited to help play an even bigger key role in improving cancer care. Cline will now take over Liv Diagnostics, with the goal to take the company and the project to a point where we can speed up the development of the existing product and reduce fatalities among breast cancer patients
Cline Scientific CEO, President and co-founder Patrik Sundh
I am excited to be involved in the continued development of this technology together with Cline as we currently have no sure means to treat metastatic disease. With this diagnostic tool we will be in a much better place to accurately diagnose, and thus correctly treat, patients at risk of this devastating disease
Breast cancer researcher Theresa Vincent, Ph D, Principal Investigator New York University & Uppsala University
Pick a time period -
Tags ( Active)

Cline Scientific’s bankruptcy application granted

Cline Scientific AB (publ) ("Cline" or the "Company") communicated earlier today that the company's board decided to submit an application to the Gothenburg district court to declare the company bankrupt. The bankruptcy application has now been granted.  Johan Sölveland, CEO of Ackordscentralen Väst AB, Gothenburg, has been appointed bankruptcy trustee.The company is listed on the Nasdaq First North Growth Market. Redeye AB is Cline Scientific's Certified Adviser.    This information is information that Cline Scientific is required to disclose pursuant to the EU Market Abuse

Cline files for bankruptcy

Cline Scientific AB (publ) ("Cline" or the "Company") has today decided to apply to put the Company into bankruptcy. The bankruptcy application is planned to be submitted today, August 12, 2024, to the Gothenburg District Court.The reason for the bankruptcy filing is that Cline has not succeeded in resolving the financial situation that was previously communicated in the first half of 2024. The company is facing continued development costs in the two projects that have been operated, StemCART and CellRACE, which must be greatly increased in order to take these forward and thus funding for

Cline Scientific: Communiqué from the Annual General Meeting

Today, 18 June, 2024, the Annual General meeting of Cline Scientific AB, 556867-8238, ("Cline Scientific" or the "Company") was held. Below is a summary of the decisions that were made. All decisions were made with the required majority.Decision on the following: Determination of the income statement and the balance sheetThe profit and loss statement and balance sheet were approved by the meeting. Dispositions regarding the company's profit or loss according to the established balance sheetThe meeting decided that the company's accumulated loss is balanced in a new account and

Annual Report for Cline Scientific AB (publ), 556867-8238, for the period 1 January – 31 December 2023

Cline Scientific AB (publ) ("Cline" or the "Company") issues the following annual report for 2023.The report is published at www.clinescientific.com/financial-reports The company is listed on the Nasdaq First North Growth Market. Redeye AB is Cline Scientific's Certified Adviser. The information was submitted for publication via the contact person listed above, at 9:15 CEST on 26 May 2024. For more information, please contact:Patrik Sundh, CEOEmail: patrik.sundh@clinescientific.comPhone: +46 703-585 088

Notice to the Annual General Meeting of Cline Scientific AB

The shareholders of Cline Scientific AB, 556867-8238, ("Cline Scientific" or "the Company"), are hereby invited to the annual general meeting on Tuesday June 18, 2024 in the Company's premises at AstraZeneca BioVentureHub. Since passage into AstraZeneca's (AZ) premises requires registration, this and registration of shareholders takes place in AZ's main entrance between 16:15-16:30, Pepparedsleden 1, 43153 Mölndal. Information about the decisions made by the AGM will be published on 18 June 2024 via the AGM Kommuniqué.Right to participate and registration Anyone who is registered as a

Cline Scientific provides an update on the company’s financial position

Cline Scientific AB (publ) ("Cline" or the "Company") would like to provide the following update on the company's financial position with reference to the previous press release on January 18th.The board has continued to work to find solutions to strengthen the company's financial position in both the short and long term. This work has not yet yielded any results and no decision regarding the company's appeal against the rejection to its application in the EIC accelerator has been received. The board continues this work with undiminished vigour.   Currently, the company's working

BioStock: Scientific Advisor on the potential of Cline’s cell therapy for cartilage damage

Cline Scientific is developing a stem cell-based treatment for early cartilage damage to avoid the development of osteoarthritis. BioStock has spoken to the company’s scientific advisor Mats Brittberg to gain insight into the treatment field, as well as how he views Cline’s innovative project.Read the full article at biostock.se : https://www.biostock.se/en/2024/03/scientific-advisor-on-the-potential-of-clines-cell-therapy-for-cartilage-damage/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

StemCART updates on achieved milestones on the way to phase 1 study

Cline Scientific AB (publ) ("Cline" or the "Company") last three experimental campaigns show successful results in measures of initial cell dose and important time aspects.During the autumn, Cline, as previously communicated, carried out three major experimental campaigns in the StemCART project. These aimed to arrive at a suitable starting dose of chondrocyte cells to initiate a clear regeneration of the cartilage tissue. Cells grown according to Cline's method and matrix were placed within a controlled injury made in cartilage tissue removed from knee joints. The goal was to test various

Bokslutskommuniké for Cline Scientific AB (publ), 556867-8238, for the period 1 January – 31 December 2023

Cline Scientific AB (publ) ("Cline" or the "Company") issues the following bokslutskommuniké for 2023.July - December 2023  · Net sales amounted to SEK 0 (0). ·  Operating profit amounted to SEK 240,145 (237,140). · Profit per average number of shares after tax amounted to 0.01 (0.01) January - December 2023 · Net sales amounted to SEK 0 (0). ·  Operating profit amounted to SEK -3,108,861 (-2,317,061) · Profit per average number of shares after tax amounted to -0.10 (-0.15) The report is published at www.clinescientific.com/financial-reports For more

Cline Scientific advisor discusses the future of cartilage damage treatment

A video interview featuring Professor Mats Brittberg, senior physician in orthopedics at Varberg Hospital and Professor at the University of Gothenburg talks about future treatments for cartilage damage has been published.Mats Brittberg, senior physician in orthopedics at Varberg Hospital and professor at the University of Gothenburg, is a scientific advisor to Cline Scientific. In the video published by BioStock, Brittberg discusses future treatments for cartilage damage and osteoarthritis. Brittberg highlights Cline's StemCART project and the work we are doing to develop an allogeneic

Cline Scientific provides an update on the company's financial position

With today's cost structure, Cline Scientific AB's (publ) expects to have cash until August 2024.The Board intends to work diligently on finding solutions to strengthen the Company's long-term financial situation. As previously communicated, the company has applied to participate in the EIC Accelerator program. The result from the latest step in the application process was a rejection due to the company being a couple of points below the limit required to move forward in the application process. The company will appeal the decision. Though, even if the company is successful with the

Information regarding trade in Clines share, CLINE B

Cline Scientific AB (publ) ("Cline" or the "Company") have the following information regarding trade in the Company share, CLINE B.Starting January 18th CLINE B will trade through the auction method introduced this afternoon by Nasdaq for certain stocks on Nasdaq First North Growth Market. According to Nasdaq this aims to assure a better price structure for those stocks with low liquidity and high spread, that is the difference between buy- and sell prices. For more information, please refer to information from Nasdaq via the links below, .IT Notice 16/23  

Medtech4Health supports capacity building in the strategy and regulatory pathway for StemCART

Cline Scientific is one of the companies included in Medtech4Health's capacity building program, to enable the strategy and regulatory pathway for StemCART.Medtech4Health's call Strengthening skills in small businesses gives companies the opportunity to hire an external person during the project period. The aim is to help the company develop and market an innovative medical technology solution. Read more about the companies included here: https://medtech4health.se/atta-nya-projekt-starker-sin-kompetens-tack-vare-medtech4health/. Medtech4Health strive to increase the number and quality of

BioStock: Cline’s CEO: “Gotten a long way with small means”

Few people have missed the fact that there is a harsh climate in the capital market for biotech companies right now. One company that has so far survived in this frosty environment is Cline Scientific, which this summer raised approximately 6.1 MSEK for the continued work of driving the main project StemCART towards clinical studies. BioStock spoke to CEO Patrik Sundh to get his thoughts on the state of the market, the financing and the value-adding milestones that the company is working towards.Read the full article at biostock.se : https://www.biostock.se/

CORRECTION: Newsletter December 2023 – Summing up the year with a Christmas message and Cline’s bright view of the future

In our Newsletter published on 7TH December 2023, a section was included related to AstraZeneca BioVentureHub. This was not officially sanctioned by the AstraZeneca BioVentureHub and thus is not to be included. We therefore ask you to disregard this part and replace it with the new version that follows. We apologize for any trouble this may have caused.   “Dear investors,   Since this past summer, Cline has been in a state of constant change and adaptation. The global financial situation and internal changes have taken up our efforts and then some. That combined with my legal

Newsletter December 2023 – Summing up the year with a Christmas message and Cline’s bright view of the future

“Dear investors,   Since this past summer, Cline has been in a state of constant change and adaptation. The global financial situation and internal changes have taken up our efforts and then some. That combined with my legal situation has made it somewhat difficult to communicate given the ongoing and unpredictable changes. Now, approaching the Christmas Holidays, the situation has stabilized, and we feel comfortable explaining a bit more in detail where we stand, how our projects actually have progressed, and how we intend to move them forward in 2024.   This year Victoria

BioStock: Cline Scientific’s CEO convicted of market manipulation

Patrik Sundh, CEO and board member of Cline Scientific, has been convicted of market manipulation by the Stockholm District Court. This was announced by the company in a press release on Tuesday. The judgment pertains to the purchase of class B shares in the company at a total value of 62,000 SEK, which was carried out in November 2022.Read the full article at biostock.se : https://www.biostock.se/en/2023/11/cline-scientifics-ceo-convicted-of-market-manipulation/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.

Judgment in the market manipulation case against Cline Scientific's CEO Patrik Sundh

Judgment has now been handed down in the case against CEO Patrik Sundh regarding market manipulation. The Stockholm district court convicted Patrik Sundh of market manipulation.Patrik Sundh, in consultation with his legal representative, has decided to appeal the verdict. However, the company's board continues to have full confidence in the company's CEO to lead the business forward. For more information, please contact: Johan Bjurquist, Chairman of the BoardPhone: +46 (0)73-747 1990

BioStock: Cline aims for stem cell breakthrough with nanotechnology

Stem cells, known for their potential to repair and heal injuries and diseases, are a hot field in biotechnology. A company involved in driving development in the area is Cline Scientific. Through its nanotechnology platform, the Swedish biotech develops a treatment that regenerates cartilage. In this article, BioStock takes a closer look at the stem cell field and where Cline’s project fits into that landscape.Read the article at biostock.se: https://www.biostock.se/en/2023/10/cline-aims-for-stem-cell-breakthrough-with-nanotechnology/ This is a press release from BioStock -

Cline and Professor Anna Ström are granted support for a joint doctoral student

Cline Scientific AB (publ) ("Cline" or the "Company") together with Professor Anna Ström at Chalmers University of Technology is given the opportunity for a joint SSF Industrial PhD student.The “Stiftelsen för Strategisk Forskning” (The Foundation for Strategic Research), SSF, finances research in natural science, technology, and medicine with approximately SEK 700 million a year. The purpose of the Industrial PhD program is to contribute to excellent research within SSF's areas of interest. The research shall promote cross-fertilization between academia and industry and contribute to the

Cline Scientific's former CEO, Patrik Sundh, returns to the post of CEO after a break

Cline Scientific AB (publ) ("Cline" or the "Company") board has, after discussions with former CEO Patrik Sundh, decided to reinstate him as CEO of the company after Patrik declared himself ready to resume the role.After a successful share issue during the summer, the board of Cline Scientific has carefully analyzed what the business should continue to focus on during the fall in order to reach the goals set for StemCART. The result of this analysis clearly shows a great need to continue the pre-clinical activities in order to build a stronger result base for a future partner. The person

BioStock: Cline Scientific ready for the next challenge

During the summer, biotech company Cline Scientific successfully carried out a share issue to raise approximately SEK 6.1 million before expenses. With the new capital, the company can take on the next challenge – to drive the stem cell project StemCART towards clinical studies. BioStock talked to CEO Hanne Evenbratt about the Cline's path forward.Read the interview with Cline Scientific's CEO Hanne Evenbratt at biostock.se: https://www.biostock.se/en/2023/09/cline-scientific-ready-for-the-next-challenge/ This is a press release from BioStock - Connecting Innovation & Capital. https://

Half-year report for Cline Scientific AB (publ), 556867-8238, for the period January 1 – June 30, 2023

Cline Scientific AB issues the following Half-Year Report for January - June 2023.Excerpt from the CEO's comment in the half-year report: “The last six months have been a challenging time for our research and development-oriented business, and this is reflected in our financial figures. Happily, our successful issue after the end of the period (during the month of July) has secured the company's finances going forward according to plan. This success shows the trust that our investors have in the company and the hopes that are placed on our projects. We hope to continue to demonstrate our

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe